转移性或局限性肾细胞癌患者健康相关生活质量问卷的研制
从FKSI-19等问卷的54个条目中,转移性RCC队列认可15条、局限性RCC队列认可6条,经专家小组和患者倡导者反馈后形成23条FKSI问卷,其中局限性RCC靶向子集11条、转移性RCC靶向子集12条。应用66%相关性阈值确保临床意义但限制了敏感性,FKSI-23工具的验证正在后续临床试验中进行。
要点
- 形成23条FKSI问卷,含局限性RCC子集11条和转移性RCC子集12条
- 转移性RCC队列认可15条,局限性RCC队列认可6条
- 采用66%相关性阈值筛选条目,可能限制敏感性
核心结论
- 成功开发FKSI-23问卷的条目子集,覆盖局限性和转移性RCC对患者HRQOL的多方面影响。
- 两种临床情况需要不同的工具以实现HRQOL的最佳测量。
- FKSI-23工具的验证正在后续临床试验中进行。
研究设计与样本
- 第一阶段为患者调查,识别相关HRQOL问题;第二阶段由专家小组修订条目;第三阶段收集患者倡导者反馈;第四阶段与FACIT库协调条目。
- 数据分析包括描述性统计和内容定性分析。
主要发现
- 从FKSI-19、EORTC QLQ-C30和EQ-5D问卷的54个条目中,转移性RCC队列认可15条,局限性RCC队列认可6条。
- 专家小组审查和患者倡导者反馈后,形成修订的23条FKSI问卷,其中局限性RCC靶向子集11条、转移性RCC靶向子集12条。
关键数值与推荐
- 应用66%相关性阈值以确保临床意义,但限制了敏感性。
- 最终工具为FKSI-23问卷,含局限性RCC子集11条和转移性RCC子集12条。
临床怎么用
- 对于局限性或转移性RCC患者,应使用对应的FKSI-23条目子集(11条或12条)评估HRQOL。
- 该工具尚未完成验证,需等待后续临床试验结果。
局限性
- 患者样本可能有限。
- 依赖患者对患者报告结局的回忆。
- 66%相关性阈值虽确保临床意义但限制了敏感性。
- 未来研究可探索补充方法以优化条目选择并提高评分可解释性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Despite significant advances in treatments for renal cell carcinoma (RCC) over the past decade, health-related quality of life (HRQOL) assessments have not been updated to reflect these developments. The aim of our study was to refine assessment of HRQOL for patients with localized or metastatic RCC. METHODS: We conducted a four-phase international study (August 2022-October 2024). Phase 1 involved a patient survey identifying relevant HRQOL issues. In phase 2, an expert panel refined items, followed by patient advocate feedback in phase 3. Phase 4 harmonized items with the Functional Assessment of Chronic Illness Therapy library for consistency across RCC stages. Data analysis included descriptive statistics and qualitative analysis of the content. KEY FINDINGS AND LIMITATIONS: Of 54 items from the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, and EuroQol Group-Five Dimension questionnaires, the metastatic RCC cohort endorsed 15 items, while the localized RCC cohort endorsed six. Expert panel review and patient advocate feedback resulted in a revised 23-item FKSI questionnaire with targeted subsets of 11 items for localized RCC and 12 items for metastatic RCC. Application of a relevance threshold of 66% ensured clinical significance but limited the sensitivity. Future studies could explore complementary approaches to refine item selection and enhance score interpretability. Study limitations include a potentially limited patient sample and reliance on patient recall of patient-reported outcomes. CONCLUSIONS AND CLINICAL IMPLICATIONS: We successfully developed item subsets of the FKSI-23 questionnaire that address the multifaceted impact of localized and metastatic RCC on patients' HRQOL. These two clinical settings required distinct tools for optimal measurement of HRQOL. Validation of the resulting FKSI-23 tool is under way in forthcoming clinical trials.
引用
- Bergerot CD, Cella D, Bergerot PG, et al. Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma. Eur Urol Oncol. 2025. PMID: 40829999. doi:10.1016/j.euo.2025.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。